Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Research Article Volume 4 Issue 8

Assessment of Prescribing Pattern of Anti-Cancer Agents in Breast Cancer Patients at West Indian Oncology Hospital

Avinash Khadela1*, Bhavin Vyas1, Shrikant Joshi1, Sandesh Lodha1 and Tushar Bambharoliya2

1Maliba Pharmacy College, Uka Tarsadia University, Surat, 394350, India
2North Carolina State University, NC USA

*Corresponding Author: Avinash Khadela, Maliba Pharmacy College, Uka Tarsadia University, Surat, 394350, India.

Received: July 24, 2020; Published: July 28, 2020

×

Abstract

Background: Breast cancer (BC) is an emerging health issue not only for the developed nation but also for developing countries and very few literatures are available on drug utilization evaluation in patients with BC.

Objective: To examine the utilization pattern of anti-cancer agents in patients with BC in an Indian oncology setup.

Setting: The oncology department of Bharat Cancer Hospital in the western part of India.

Methods: In a descriptive-observational study treatment orders of patients on chemotherapy for BC were reviewed and the treatment pattern was assessed. Cancer patients who were above 18 years and are on chemotherapy along with supportive care medications were enrolled.

Main outcome measure: The most frequently used anti-neoplastic and supportive care agents, as a percentage of treatment.

Results: A total of 201 patients fulfilling inclusion criteria were enrolled in the study. The majority of the enrolled patients were in the age group of 50 - 69 (54.7%) and females (100%). The family history was found insignificant as a risk factor for the development of BC. The most common types of BC were ductal infiltrating (46.3%), ductal invasive (35.8%) and metastatic (9.0%) and most of them were in stage III (53.2%) and II (25.9%). Amongst them, 18.4% and 16.4% of patients were suffering from oestrogen and progesterone positive tumors respectively whereas 6.5% was HER2 positive. Tamoxifen and anastrozole or letrozole were prescribed in oestrogen and progesterone positive BC respectively. Adjuvant chemotherapy (78.1%) followed by Neo-adjuvant chemotherapy (16.9%) were frequently prescribed. Amongst all anti-neoplastic agents prescribed cyclophosphamide (92.0%) was highly prescribed followed by doxorubicin (79.1%) and fluorouracil (37.8%). Dexamethasone (61.2%), ondansetron (50.8%), palonosetron (32.8%), pantoprazole (25.4%), and peg-filgrastim (16.9%) were commonly prescribed supportive care medications.

Conclusion: This study has shown that the majority of BC patients received alkylating agents followed by anthracycline derivatives and taxanes. Moreover, supportive care agents such as dexamethasone, ondansetron, and pantoprazole were administered in the majority of the patients along with peg-filgrastim or filgrastim to minimize chemotherapy induce toxicities.

Keywords: Breast Cancer; Chemotherapy; Prescribing patterns; Supportive Care

×

References

  1. World health organization (2020).
  2. Malvia S., et al. “Epidemiology of breast cancer in Indian women”. Asia-Pacific Journal of Clinical Oncology 13 (2017): 289-295.
  3. Statistics of breast cancer in India (2020).
  4. Tfayli A., et al. “Breast cancer in low- and middle-income countries: An emerging and challenging epidemic”. Journal of Oncology 2010 (2010): 1-5.
  5. Giordano SH., et al. “Breast cancer treatment guidelines in older women”. Journal of Oncology 23(4) (2005): 783-791.
  6. Smith IC., et al. “Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel”. Journal of Oncology6 (2002): 1456-1466.
  7. Rodenhuis S., et al. “Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer”. Annuals of Oncology4 (2006): 588-596.
  8. Walshe JM., et al. “Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer”. Journal of Oncology36 (2006): 5769-5779.
  9. Ghoncheh M., et al. “Incidence and Mortality and Epidemiology of Breast Cancer in the World”. Asian Pacific Journal of Cancer PreventionS3 (2016): 43-46.
  10. Chopra B., et al. “Age shift: breast cancer is occurring in younger age groups—is it true?” Clinical Cancer Investigation Journal 3 (2014): 526-529.
  11. Sandhu D., et al. “Profile of breast cancer patients at a tertiary care hospital in north India”. Indian Journal of Cancer 47 (2010): 16-22.
  12. Brewer HR., et al. “Family history and risk of breast cancer: an analysis accounting for family structure”. Breast Cancer Research and Treatment 1 (2017): 193-200.
  13. Singletary SE. “Rating the Risk Factors for Breast Cancer”. Annuals of Surgery4 (2003): 474-482.
  14. Bodicoat DH., et al. “Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study”. Breast Cancer Research 1 (2014): R18.
  15. Agarwal G and Ramakant P. “Breast Cancer Care in India: The Current Scenario and the Challenges for the Future”. Breast Care (Basel)1 (2008): 21-27.
  16. Desai SB., et al. “Hormone receptor status of breast cancer in India: a study of 798 tumours”. Breast 5 (2000): 267-270.
  17. Sandhu GS., et al. “Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis”. The Journal of Global Oncology 6 (2016): 412-421.
  18. Poole CJ., et al. “Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer”. The New England Journal of Medicine 18 (2006): 1851-1862.
  19. Joshi SC., et al. “Role of radiotherapy in early breast cancer: an overview”. International Journal of Health Sciences (Qassim). 1.2 (2007): 259-264.
  20. Campbell HE., et al. “The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses”. European Journal of Cancer17 (2011): 2517-2530.
  21. Jones KL and Buzdar AU. “A review of adjuvant hormonal therapy in breast cancer”. Endocrine-Related Cancer 3 (2004): 391-406.
  22. Iqbal N and Iqbal N. “Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications”. Molecular Biology International 2014 (2014): 852748.
  23. Carpenter RL and Lo HW. “Regulation of Apoptosis by HER2 in Breast Cancer”. Journal of Carcinogenesis and Mutagenesis 2013 (2013): 003.
  24. Mouridsen HT and Robert NJ. “The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women”. European Journal of Cancer12 (2005): 1678-1689.
  25. Ramalakshmi S., et al. “A study on prescribing trends of supportive care drugs used in cancer chemotherapy in a tertiary care teaching hospital”. IJOPP 6 (2013): 36-39.
  26. Khadela A and Vyas B. “Assessment of the utilization pattern of chemotherapy agents in patients with head and neck cancer in an oncology hospital”. Drugs and Therapy Perspectives7 (2020): 303-309.
×

Citation

Citation: Avinash Khadela.,et al. “Assessment of Prescribing Pattern of Anti-Cancer Agents in Breast Cancer Patients at West Indian Oncology Hospital". Acta Scientific Cancer Biology 4.8 (2020): 19-26.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 25, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US